PROSTACOX : Metastatic Prostate Chemotherapy

Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients

NCT00714376 ·Status: TERMINATED ·Phase: PHASE2

Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00005096 ·Status: COMPLETED ·Phase: PHASE2

Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer

NCT00494338 ·Status: TERMINATED ·Phase: PHASE2

A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer

NCT00134706 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome

NCT04622761 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

NCT00116142 ·Status: COMPLETED ·Phase: PHASE3

Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients

NCT00127088 ·Status: SUSPENDED ·Phase: PHASE2

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

NCT01296243 ·Status: UNKNOWN ·Phase: PHASE2

Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer

NCT00022399 ·Status: COMPLETED ·Phase: PHASE2

Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer

NCT00577356 ·Status: TERMINATED ·Phase: PHASE2

Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer

NCT00728663 ·Status: COMPLETED ·Phase: PHASE2

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

NCT01683994 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer

NCT00215345 ·Status: UNKNOWN ·Phase: PHASE2

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02905318 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT01718353 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

NCT00541281 ·Status: COMPLETED ·Phase: PHASE2

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer

NCT00744497 ·Status: COMPLETED ·Phase: PHASE3

Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway

NCT03652493 ·Status: COMPLETED ·Phase: PHASE2

Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs

NCT04662996 ·Status: COMPLETED ·Phase: NA

Telaglenastat + Talazoparib In Prostate Cancer

NCT04824937 ·Status: UNKNOWN ·Phase: PHASE2

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

NCT00165399 ·Status: COMPLETED ·Phase: PHASE2

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924 ·Status: RECRUITING ·Phase: PHASE3

Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting

NCT03912883 ·Status: ACTIVE_NOT_RECRUITING

Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy

NCT00073970 ·Status: TERMINATED ·Phase: PHASE2

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00003614 ·Status: COMPLETED ·Phase: PHASE2